Novo Biosciences Receives Federal Grant to Advance Potential Heart Drug

According to EurekaAlert, Novo Biosciences Inc., a spinoff of the MDI Biological Laboratory in Bar Harbor, Maine, has announced that it has received a two-year, $1.5 million Small Business Innovation Research (SBIR) grant from the National Institutes of Health (NIH) for the development of MSI-1436 as a potential regenerative medicine therapy for the treatment of patients who have suffered an acute heart attack. “We believe MSI-1436 has enormous potential,” said Kevin Strange, Ph.D., CEO of Novo Biosciences and president of the MDI Biological Laboratory. “No drug now exists to treat heart attack. Heart disease is the the world’s leading killer. In order to advance MSI-1436 into clinical trials, we need to first test its effectiveness in a large animal model. We are deeply grateful to the National Heart, Lung, and Blood Institute for making this possible.” Read more

Related Posts

On the Record: Roux Institute’s Lars Perkins helps startups take off

Lars Perkins, a former software entrepreneur, Google executive and certified flight instructor who once flew planes for lifesaving “adventure philanthropy,” is managing...

28 November 2022

UNE to begin building new medical school at Portland campus

The University of New England is about to start a $93 million project to move the state’s only medical school from...

28 November 2022

Portland Planning Board recommends zoning changes for Roux Institute redevelopment

The Portland Planning Board is recommending that the city adopt zoning changes requested by the developers of a new graduate school...

22 November 2022